This is a double-blind, placebo-controlled, crossover study testing whether Vyvanse
(lisdexamfetamine; LDX) improves executive functioning (EF) in 100 postmenopausal women who
report onset of EF difficulties after oophorectomy. This study involves magnetic resonance
imaging (MRI) to see how LDX affects brain chemistry while undergoing two 6-week trials of
the study drug and placebo capsules.
UPDATE: We have recently updated this protocol (09/2020) to offer a remote version of the
study that can be completed entirely from the participant's home. This alternate version of
the study eliminates travel, the MRI, and blood draws.